Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia

Aseffa, A; Bedru, A; Yamuah, L; Arga, D; Worku, A; Chandramohan, D; Nelson, CB; Engers, HD; (2007) Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. Vaccine, 25. A79-A82. ISSN 0264-410X DOI:

Full text not available from this repository.


A phase 11 open and parallel reactogenicity, immunogenicity and safety trivalent meningitis vaccine (Mencevax) trial was conducted on 413 volunteer 2-29-year-old rural residents in Ethiopia in November/December 2005. Adverse events (AE) were monitored at I h, 1, 2, 3, 7 and 28 days after vaccination. No serious AE occurred except for burn injury (one) and severe malaria (one) after day 28. Irritability (45/411), loss of appetite (27/411), pain at injection site (26/412), dizziness (18/409), crying (14/411), insomnia, headache and diarrhoea (13/411) were the most frequent AEs. Overall, the vaccine is safe in the age groups studied. (C) 2007 Elsevier Ltd. All rights reserved.

Item Type: Article
Keywords: Adolescent, Adult, Aged, Child, Child, Preschool, Dizziness, etiology, Ethiopia, Follow-Up Studies, Humans, Meningitis, Meningococcal, immunology, prevention & control, Meningococcal Vaccines, administration & dosage, adverse effects, immunology, Middle Aged, Neisseria meningitidis, Serogroup W-135, immunology, Pain, etiology, Sleep Initiation and Maintenance Disorders, etiology, Time Factors, Treatment Outcome
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Research Centre: Centre for Maternal, Reproductive and Child Health (MARCH)
Vaccine Centre
PubMed ID: 17548138
Web of Science ID: 249521900016


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item